



## Total Synthesis of Cyclostelletamine C, a Bispyridinium Macrocyclic Alkaloid Having Muscarinic Acetylcholine Receptor Antagonistic Activity


Hideki Anan,<sup>a,\*</sup> Norio Seki,<sup>a</sup> Osamu Noshiro,<sup>a</sup> Kazuo Honda,<sup>a</sup> Kenichi Yasumuro,<sup>a</sup> Teruaki Ozasa<sup>a</sup>  
 and Nobuhiro Fusetani<sup>b</sup>

<sup>a</sup>Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21, Miyukigaoka, Tsukuba, Ibaraki 305, Japan.


<sup>b</sup>Laboratory of Aquatic Natural Products Chemistry, Graduate School of Agricultural Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan.

**Abstract:** Cyclostelletamine C (**1**), a bispyridinium macrocyclic compound having muscarinic acetylcholine receptor antagonistic activity, was synthesized by the stepwise ring closure method via 3-(13-hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium trifluoromethanesulfonate (**21**). Through this study, the structure of naturally originating **1** was synthetically and biologically confirmed. Copyright © 1996 Published by Elsevier Science Ltd

Bioactive alkaloids of natural sources have been well investigated for drug serendipity; some pyridinium compounds have been discovered from marine sponges.<sup>1)</sup> Previously, we reported that novel macrocyclic pyridinium alkaloids, cyclostelletamines A-F, were isolated as muscarinic acetylcholine receptor antagonists.<sup>2)</sup> Cyclostelletamines consist of two 1,3-disubstituted pyridinium moieties linked to long aliphatic chains.



Faulkner and coworkers isolated polymeric pyridinium compounds from marine sponges as activators of epidermal growth factor (EGF).<sup>3)</sup> In order to confirm their structures, they synthesized the cyclic pyridinium dimer, trimer, tetramer, and oligomer, in which hydroxyalkylpyridines were cyclized under high concentration conditions (330 mM), and each cyclic oligomer was chromatographically isolated (Scheme 1). In this case, however, the mass-to-charge ratios of the oligomers ( $C_xH_yN^+$ )<sub>n</sub> are the same overall values of n.




Scheme 1

We also attempted to confirm the proposed structures of cyclostelletamines by the synthesis of cyclostelletamine C (**1**), the major compound of the cyclostelletamines, by a stepwise ring construction strategy. The synthetic compound was identical with natural cyclostelletamine C in several respects.


## SYNTHESIS

Our strategy was as follows (Scheme 2); the  $\omega$ -phosphonized alkyl group was connected to the nitrogen of the  $\omega$ -O-protected alkylpyridine and condensed with the second pyridyl group by Wittig reaction. Cyclization was then performed under highly dilute conditions to avoid polymerization.




Scheme 2

12-Benzyloxydodecanol (**3**), which was obtained by monobenylation of 1,12-dihydroxydodecane (**2**), was treated with  $I_2$ ,  $PPh_3$  and imidazole at rt to give iodide **4** in an excellent yield.<sup>4)</sup> **4** was phosphonized by heating under reflux with  $PPh_3$  in toluene. The phosphonium salt **5** thus obtained was treated with  $BuLi$  followed by nicotinaldehyde (**6**) in THF at  $-20\text{ }^\circ\text{C}$  to give monoolefinic product **7**, which furnished 13-benzyloxytridecylpyridine (**8**) upon hydrogenation.




Scheme 3

For preparation of the other long chain, an acetyl group was chosen instead of the benzyl group in **3**. As shown in Scheme 4, the alcohol **9** was converted to 12-acetoxyposphonium salt (**11**) in the same manner as described above. Saponification of **11** with  $NaOH$  in aqueous  $MeOH$  afforded alcohol **12**, which was condensed with benzyloxytridecylpyridine (**8**) by treating with  $Tf_2O$  and collidine in  $CH_2Cl_2$  to give the pyridiniophosphonium salt **13**.<sup>9)</sup>




Scheme 4

Because the reactivity of the ylide generated from **13** was low, excess amounts of **6** were required (Scheme 5). An equivalent amount of **6** led to production of only diphenylphosphinoyl, which was produced by the hydration of the ylide. The use of 4 equivalents of **6** resulted in the desired vinylpyridine **14** in 43% yield.



Scheme 5

In spite of the fact that **14** had four reducible functional groups, namely a benzyl ether, an olefin, pyridine and pyridinium rings, catalytic hydrogenation of **14** on 10% Pd/C at rt over 85 min afforded **15** (36% yield).<sup>6</sup>



Scheme 6

The next problem was selective deprotection of a benzyl group of **15**. Reaction conditions were therefore examined with simple model compounds **8** and **16**. 1-Butyl-3-(3-benzyloxypropyl)pyridinium iodide (**16**) was easily deprotected with TMSI in  $\text{CH}_2\text{Cl}_2$ .<sup>7</sup> A large excess of TMSI and a longer reaction time converted the hydroxyl group to iodide. However, in the case of **8**, 13-hydroxytridecylpyridine (**19**) was produced in low yield

As shown in Figure 1A, the dimeric compound **1a** revealed a base peak at  $m/z$  669 which was assigned to

$[M+TfO]^+$  by high resolution FAB mass spectral analysis. Also, **1b** and **1c** revealed prominent peaks assigned to  $[M+CF_3CO_2]^+$  ( $m/z$  633) and  $[M+Cl]^+$  ( $m/z$  555), respectively. In the case of natural cyclostelletamine C (**1**), a base peak ( $m/z$  519) and prominent peaks ( $m/z$  633, 260) were observed, which were assigned to  $[M-H]^+$ ,  $[M+CF_3CO_2]^+$ , and  $[M/2]^+$ , respectively.<sup>9)</sup> Of course, synthetic **1a-c** revealed prominent peaks at  $m/z$  260 and 519. Relative intensities of  $[M-H]^+$  peaks vs  $[M+X]^+$  peaks were 14%, 127%, and 97% for **1a**, **1b**, and **1c**, respectively. In this series, the  $[M-H]^+$  ion was thought to be produced by a Hoffman-type elimination during the FAB ionization process.<sup>2,3)</sup> This result indicated that the  $(M^{2+}+CF_3CO_2^-)$  ion pair caused a Hoffman-type elimination more easily than the  $(M^{2+}+TfO^-)$  ion pair. Thus, natural cyclostelletamine C (**1**) might reveal a relatively weak prominent peak at  $m/z$  633. In contrast, the monomeric compound **21** exhibited a prominent peak only at  $m/z$  260 (Figure. 1D).




Fig. 1. Positive FAB-MS spectra of **1a** (A), **1b** (B), **1c** (C), and **21** (D).

Because natural cyclostelletamines<sup>2)</sup> blocked the binding of [ $^3H$ ]-methyl quinuclidinyl benzilate to muscarinic receptor subtypes  $M_1$  (rat brain),  $M_2$  (rat heart), and  $M_3$  (rat salivary gland),<sup>10)</sup> synthetic **1a** and related compounds **19**, **20** and **21** were examined in the same assay. As shown in Table 2, natural and synthetic **1** showed almost the same activity; whereas, synthetic derivatives **19**, **20** and **21** were less active. This demonstrated the structural identity of natural and synthetic **1**. **20** and **21** each have one positively charged pyridinium ion, which may be responsible for binding to the TM III (transmembrane helix III) Asp residue in the ligand-binding domain of muscarinic receptors as in the case of cyclostelletamines.<sup>11)</sup>

Table. Antagonistic Activity of Synthetic and Natural Compounds for Muscarinic Receptors ( $IC_{50}$ : mean $\pm$ SE,  $\mu$ g/mL).

	M <sub>1</sub>	M <sub>2</sub>	M <sub>3</sub>
<b>1a</b>	0.090 $\pm$ 0.003	0.089 $\pm$ 0.015	0.195 $\pm$ 0.010
<b>1</b> (natural)	0.121 <sup>a)</sup>	0.054 <sup>a)</sup>	0.144 <sup>a)</sup>
<b>19</b>	4.007 $\pm$ 0.174	4.883 $\pm$ 0.169	3.307 $\pm$ 0.131
<b>20</b>	0.768 $\pm$ 0.014	1.090 $\pm$ 0.025	0.917 $\pm$ 0.036
<b>21</b>	1.707 $\pm$ 0.079	2.843 $\pm$ 0.042	2.947 $\pm$ 0.038

a) see reference 2.

In conclusion, the structure of **1** was synthetically and biologically confirmed. During this study, we found the relative compounds of **1**, which had positively charged pyridinium ions, showed muscarinic receptor binding affinity. However, their structure-activity relationships were not clear.

## EXPERIMENTAL SECTION

All solvents except tetrahydrofuran were used without purification and dried on molecular sieves if necessary. Tetrahydrofuran was distilled over sodium benzophenone ketyl. Nuclear magnetic resonance (NMR) spectra were recorded on a JEOL GSX-400, GSX-500, or EX90 spectrometer using Me<sub>4</sub>Si as an internal standard. GC mass spectra were recorded on a VG TRIO 1000 or HP 5890GC and 5970MSD in CI or EI mode, respectively. FAB and high-resolution mass spectra were recorded on JEOL DX-300 and VG ZAB-VSE mass spectrometers, respectively. UV spectra were measured with a Shimadzu UV-2200. Melting points were determined with a Yanaco MP-500D and were uncorrected. Elemental analysis was performed on a Yanaco MT-5. HPLC was carried out using a Hitachi L-6200 intelligent pump, L-4000 UV detector, D-2500 recorder and Shiseido CAPCELL PAK C<sub>18</sub> SG120 (4.6 x 250 mm) or L-column ODS (4.6 x 250 mm). For thin-layer chromatography (TLC), Merck Silica gel 60 F<sub>254</sub> precoated plates were used. For column chromatography, Wakogel C-200, Cosmosil 75C<sub>18</sub>-opn, YMC-GEL ODS and Sephadex LH-20 were used. For anion exchange, Amberlite IRA-400 was used.

**12-Benzoyloxydodecanol (3).** Sodium hydride (5.93 g, 247 mmol) was added to a solution of 1,12-dihydroxydodecane (**2**, 50 g, 247 mmol) in THF (800 mL) and the mixture was stirred at 40 °C for 80 min. Benzylbromide (14.7 mL, 124 mmol) was added to the mixture, and the mixture was heated at 60 °C for 19 h. After quenching with iced saturated NH<sub>4</sub>Cl aqueous solution, the aqueous layer was extracted three times with

EtOAc. The combined organic layers were washed with brine, dried over  $\text{MgSO}_4$ , and concentrated. The residue was purified by silica gel column chromatography (EtOAc-hexane, 1:20 to 1:4) to give **3** (22.9 g, 63%) as a colorless oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.1-1.7 (m, 21H), 3.46 (t, 2H,  $J=6.4$  Hz), 3.66 (t, 2H,  $J=5.1$  Hz), 4.50 (s, 2H), 7.33 (m, 5H); GC-MS (EI) 292 ( $\text{M}^+$ ); HRMS (EI) obsd.  $m/z=292.2396$ ,  $\text{C}_{19}\text{H}_{32}\text{O}_2$  requires  $m/z$  292.2402.

**Benzyl-12-iodododecylether (4).** Imidazole (8.61 g, 126 mmol), triphenylphosphine (33.2 g, 127 mmol) and iodine (25.7 g, 101 mmol) were added to a solution of **3** (14.8 g, 50.6 mmol) in benzene (300 mL), and the mixture was stirred at ambient temperature for 30 min. To the reaction mixture was added saturated  $\text{Na}_2\text{SO}_3$  aqueous solution until the yellow color disappeared. The organic layer was washed with brine, dried over  $\text{MgSO}_4$ , and concentrated. The residue was purified by silica gel column chromatography (benzene-hexane, 1:10 then EtOAc-hexane, 1:3) to afford **4** (20.3 g, 100%) as a colorless oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.1-1.9 (m, 20H), 3.18 (t, 2H,  $J=7.0$  Hz), 3.46 (t, 2H,  $J=6.3$  Hz), 4.50 (s, 2H), 7.3-7.4 (m, 5H); GC-MS (EI) 402 ( $\text{M}^+$ ); HRMS (EI) obsd.  $m/z=402.1424$ ,  $\text{C}_{19}\text{H}_{31}\text{OI}$  requires  $m/z$  402.1420.

**12-Benzyloxydodecyltriphenylphosphonium iodide (5).** A solution of **4** (20.2 g, 50.1 mmol) and triphenylphosphine (12.5 g, 47.7 mmol) in toluene (200 mL) was heated to reflux for 18 h. After cooling to rt, hexane (50 mL) was added to the mixture. The lower layer was collected and concentrated to give **5** (27.7 g, 88%) as a colorless viscous syrup:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.1-1.7 (m, 20H), 3.46 (t, 2H,  $J=6.3$  Hz), 3.5-3.8 (m, 2H), 4.49 (s, 2H), 7.3-7.3 (m, 5H), 7.7-8.0 (m, 15H); MS (FAB) 537 ( $\text{M}^+$ ); HRMS (FAB) obsd.  $m/z=537.3321$ ,  $\text{C}_{37}\text{H}_{46}\text{OP}$  requires  $m/z$  537.3286.

**3-(13-Benzyloxy-1-tridecenyl)-pyridine (7).** 1.61 M BuLi in hexane (28.4 mL, 45.7 mmol) was added to a solution of **5** (27.6 g, 41.6 mmol) in THF (420 mL) at  $-20^\circ\text{C}$  and the mixture was stirred for 30 min at the same temperature. Nicotinaldehyde (4.11 mL, 43.7 mmol) and THF (50 mL) was then added to the mixture, which was stirred at the same temperature for 40 min and then warmed to  $4^\circ\text{C}$  for 13 h. The reactant was quenched with ice and the organic layer was separated. The aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over  $\text{Na}_2\text{SO}_4$ , and concentrated. The residue was purified by silica gel column chromatography (EtOAc-hexane, 1:5) to furnish **7** (*E,Z*-mixture, 13.0 g, 85%) as a colorless oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.1-1.7 (m, 18H), 2.15-2.45 (m, 2H), 3.46 (t, 2H,  $J=6.3$  Hz), 4.5 (s, 2H), 5.66-5.96 (m, 1H), 6.28-6.46 (m, 1H), 7.1-7.25 (m, 1H), 7.29-7.32 (m, 5H), 7.50-7.66 (m, 1H), 8.40-8.60 (m, 2H); GC-MS (EI) 365 ( $\text{M}^+$ ); HRMS (EI) obsd.  $m/z=365.2689$ ,  $\text{C}_{25}\text{H}_{35}\text{NO}$  requires  $m/z$  365.2719.

**3-(13-Benzyloxytridecyl)pyridine (8).** A mixture of **7** (12.9 g, 35.3 mmol), 10% Pd/C (646 mg) and EtOH (650 mL) was stirred vigorously under a  $\text{H}_2$  atmosphere. After absorption of a theoretical amount of  $\text{H}_2$ , the mixture was filtered and concentrated. The residue was purified by silica gel column chromatography (EtOAc-hexane, 1:5) to give **8** (11.7 g, 90%) as a colorless oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.05-1.7 (m, 22H), 2.60 (t, 2H,  $J=8.0$  Hz), 3.46 (t, 2H,  $J=6.4$  Hz), 4.50 (s, 2H), 7.15 (d, 1H,  $J=8.0$  Hz), 7.29-7.35 (m, 5H), 7.48 (dt, 1H,  $J=2.0, 8.0$ ), 8.38-8.50 (m, 2H);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  26.14, 29.09, 29.34, 29.42, 29.47, 29.52, 29.71, 31.06, 32.94, 70.47, 72.78, 123.14, 127.37, 127.53, 128.24, 135.69, 137.90, 138.67, 147.06, 149.88; MS (FAB) 368 ( $\text{M}+\text{H}^+$ ); HRMS (EI)

obsd.  $m/z=367.2837$ ,  $C_{25}H_{37}NO$  requires  $m/z$  367.2875.

**12-Hydroxydodecylacetate (9).** Acetylchloride (0.806 mL, 11.3 mmol) was added to a solution of **3** (3.0 g, 10.3 mmol) in  $CH_2Cl_2$  (30 mL), and triethylamine (1.58 mL, 11.3 mmol) in  $CH_2Cl_2$  (5 mL) was added to the mixture at 4°C. After stirring at rt for 90 min, the reaction was quenched by the addition of ice-water. The organic layer was washed with brine, dried over  $MgSO_4$ , and concentrated. The residue was purified by silica gel column chromatography (EtOAc-hexane, 1:20) to give 12-benzyloxylododecylacetate (3.31 g, 96%) as a colorless oil:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.1-1.75 (m, 20H), 2.04 (s, 3H), 3.47 (t, 2H,  $J=6.4$  Hz), 4.05 (t, 2H,  $J=6.5$  Hz), 4.5 (s, 2H), 7.33 (s, 5H); GC-MS (CI) 335 (M+H) $^+$ ; HRMS (EI) obsd.  $m/z=334.2472$ ,  $C_{21}H_{34}O_3$  requires  $m/z$  334.2508.

A mixture of the above ester (3.24 g, 9.69 mmol), 10% Pd/C (160 mg), and EtOH (130 mL) was stirred vigorously under a  $H_2$  atmosphere. After absorption of a theoretical amount of  $H_2$ , the mixture was filtered and concentrated to give **9** (2.34 g, 99%) as a colorless oil:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.1-1.8 (m, 21H), 2.04 (s, 3H), 3.64 (q, 2H,  $J=5.5$  Hz), 4.05 (t, 2H,  $J=6.5$  Hz); GC-MS (CI) 245 (M+H) $^+$ ; HRMS (EI) obsd.  $m/z=245.2121$ ,  $C_{14}H_{26}O_3$  requires  $m/z$  245.2117.

**12-Iodododecylacetate (10).** This was prepared in the same manner as described above for **4** in a 98% yield (a slightly yellowish oil):  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.2-2.0 (m, 20H), 2.04 (s, 3H), 3.19 (t, 2H,  $J=7.0$  Hz), 4.05 (t, 2H,  $J=6.5$  Hz); GC-MS (CI) 355 (M+H) $^+$ ; HRMS (EI) obsd.  $m/z=355.1121$ ,  $C_{14}H_{26}O_2I$  requires  $m/z$  355.1134.

**12-Acetoxydodecyltriphenylphosphonium iodide (11).** This was prepared in the same manner as described above for **5** in a 95% yield (a colorless oil):  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.1-1.9 (m, 20H), 2.03 (s, 3H), 3.48-3.85 (m, 2H), 4.04 (t, 2H,  $J=6.4$  Hz), 7.65-8.05 (m, 15H); MS (FAB) 489 (M) $^+$ ; HRMS (FAB) obsd.  $m/z=489.2894$ ,  $C_{32}H_{42}O_2P$  requires  $m/z$  489.2922.

**12-Hydroxydodecyltriphenylphosphonium iodide (12).** A solution of **11** (5.92 g, 9.60 mmol) and 1 M NaOH (10.1 mL) in MeOH (59 mL) was stirred at rt for 140 min. 1 M HCl (0.48 mL) was then added to the solution and the solution was concentrated. The residue was purified by silica gel (inactivated with 6%w/w water) column chromatography ( $CHCl_3$ -MeOH, 20:1) to give **12** (5.35 g, 97%) as a colorless oil:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.0-1.8 (m, 21H), 3.4-3.85 (m, 4H), 7.5-8.0 (m, 15H); MS (FAB) 447 (M) $^+$ ; HRMS (FAB) obsd.  $m/z=447.2859$ ,  $C_{30}H_{40}OP$  requires  $m/z$  447.2817.

**3-(13-Benzyloxytridecyl)-1-[(12-triphenylphosphonio)dodecyl]pyridinium (13).**  $Tf_2O$  (2.56 mL, 15.3 mmol) and collidine (2.02 mL, 15.3 mmol) were added to a solution of **12** (6.8 g, 11.8 mmol) in  $CH_2Cl_2$  (60 mL), and **8** (4.35 g, 11.8 mmol) in  $CH_2Cl_2$  (10 mL) was added to the mixture. The solution was stirred at rt for 75 min and then at 30 °C for 90 min. MeOH (30 mL) was added to the solution at 4 °C, to which  $Na_2SO_3$  was added, and the mixture was stirred at rt for 30 min. After filtration and concentration, the residual mixture was purified by silica gel (inactivated with 15%w/w water) column chromatography ( $CHCl_3$ -MeOH- $NH_3$ aq, 100:10:1) to give **13** (7.39 g, 68% $^b$ ) as a yellowish viscous syrup:  $^1H$  NMR ( $CDCl_3$ )  $\delta$  1.16-1.40 (m, 32H), 1.52-1.72 (m, 8H), 2.00 (m, 2H), 2.85 (t, 2H,  $J=8.1$  Hz), 3.23-3.32 (m, 2H), 3.46 (t, 2H,  $J=6.6$  Hz), 4.49 (s, 2H), 4.67 (t, 2H,  $J=7.8$  Hz), 7.25-7.35 (m, 5H), 7.63-7.84 (m, 15H), 7.96 (dd, 1H,  $J=6.1$ , 7.8 Hz), 8.18 (d, 1H,  $J=7.8$  Hz), 8.94 (d, 1H,  $J=6.1$  Hz),



8.98 (s, 1H); MS (FAB) 796 (M-H)<sup>+</sup>, 946 (M+TfO)<sup>+</sup>; HRMS (FAB) obsd. *m/z*=796.5591, C<sub>55</sub>H<sub>75</sub>NOP requires *m/z* 796.5586; obsd. *m/z*=946.5180, C<sub>56</sub>H<sub>76</sub>NO<sub>4</sub>F<sub>3</sub>PS requires *m/z* 946.5185.

**3-(13-Benzyloxytridecyl)-1-[13-(3-pyridyl)tridec-12-enyl]pyridinium Trifluoromethanesulfonate (14).** **13** (817 mg, 0.747 mmol) in THF (7.5 mL) was added to a mixture of sodium hydride (54 mg, 2.24 mmol) and THF (7.5 mL) at -20 °C, and **6** (0.281 mL, 2.99 mmol) was added to the mixture. The mixture was stirred at rt for 16 h and then at 30 °C for 3 h. The reaction was quenched by the addition of saturated NH<sub>4</sub>Cl aqueous solution at 4 °C and extracted with EtOAc. The organic layer was separated and the aqueous layer was extracted with CHCl<sub>3</sub> twice. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The residue was purified by reversed phase column chromatography (MeOH-H<sub>2</sub>O, 9:1) followed by LH-20 gel column chromatography (MeOH) to afford **14** (249 mg, 43%) as a slightly yellowish oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.00-1.52 (m, 30H), 1.55-1.73 (m, 6H), 1.95-2.02 (m, 2H), 2.10-2.30 (m, 4H), 2.84 (t, 2H, *J*=7.6 Hz), 3.46 (t, 2H, *J*=6.8 Hz), 4.50 (s, 2H), 4.97 (t, 2H, *J*=7.3 Hz), 5.77-5.82 (m, 1H), 6.30-6.36 (m, 1H), 7.10-7.38 (m, 6H), 7.55-7.66 (m, 1H), 7.84, 7.98 (dd, 1H, *J*=6.1, 7.6 Hz), 8.11, 8.15 (d, 1H, *J*=7.6 Hz), 8.43, 8.52 (br, 2H), 9.11, 9.17 (s, 1H), 9.37, 9.42 (d, 1H, *J*=6.1 Hz); MS (FAB) 625 (M)<sup>+</sup>; HRMS (FAB) obsd. *m/z*=625.5087, C<sub>43</sub>H<sub>65</sub>N<sub>2</sub>O requires *m/z* 625.5097.

**3-(13-Benzyloxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium Trifluoromethanesulfonate (15).** A mixture of **14** (53.0 mg, 68.5 μmol), 10% Pd/C (5 mg) and EtOH (5 mL) was stirred vigorously under a H<sub>2</sub> atmosphere for 85 min. After filtration and concentration, the residue was purified by reversed phase column chromatography (MeOH-H<sub>2</sub>O, 9:1) to give **15** (19.0 mg, 36%) as a colorless oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.05-1.40 (m, 34H), 1.55-1.72 (m, 8H), 2.01 (quint., 2H, *J*=7.3 Hz), 2.62 (t, 2H, *J*=7.6 Hz), 2.86 (t, 2H, *J*=7.9 Hz), 3.46 (t, 2H, 6.7 Hz), 4.50 (s, 2H), 4.98 (t, 2H, *J*=7.3 Hz), 7.23-7.37 (m, 6H), 7.55 (d, 1H, *J*=7.3 Hz), 7.99 (dd, 1H, *J*=5.5, 7.9 Hz), 8.17 (d, 1H, *J*=7.9 Hz), 8.40-8.50 (br, 2H), 9.09 (s, 1H), 9.43 (d, 1H, *J*=5.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 26.14, 26.21, 29.06, 29.26, 29.32, 29.44, 29.49, 29.59, 29.78, 30.44, 31.02, 32.09, 32.82, 33.00, 62.09, 70.56, 72.87, 123.63, 127.47, 127.62, 127.92, 128.35, 136.64, 138.73, 143.05, 143.81, 144.18, 144.40, 144.40, 146.34, 149.06; MS (FAB) 627 (M)<sup>+</sup>; HRMS (FAB) obsd. *m/z*=627.5241, C<sub>43</sub>H<sub>67</sub>N<sub>2</sub>O requires *m/z* 627.5253.

**3-(13-Hydroxytridecyl)-1-[13-(3-pyridyl)tridecyl]pyridinium Trifluoromethanesulfonate (20).** TfOH (11.8 μL, 134 μmol) was added to a solution of **15** (52.0 mg, 66.9 μmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at rt, followed by the addition of TMSI (19.0 μL, 134 μmol). After 1 h, TMSI (9.5 μL, 66.9 μmol) was again added to complete the reaction, and the mixture stirred for a further 1 h. MeOH (3 mL) and 40% MeNH<sub>2</sub> in MeOH (2 mL)<sup>12)</sup> were added to the mixture, which was stirred at rt for 2 h. After concentration, the residue was purified by LH-20 gel column chromatography (MeOH) followed by reversed phase column chromatography (MeOH-H<sub>2</sub>O, 9:1) to give **20** (22.0 mg, 48%) as a colorless amorphous solid: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.05-1.40 (m, 34H), 1.56 (quint., 4H, *J*=7.4 Hz), 1.62 (quint., 2H, *J*=7.3 Hz), 1.71 (quint., 2H, *J*=7.9 Hz), 2.02 (quint., 2H, *J*=7.3 Hz), 2.34 (br, 1H), 2.62 (t, 2H, *J*=7.6 Hz), 2.88 (t, 2H, *J*=7.7 Hz), 3.63 (t, 2H, 6.7 Hz), 4.98 (t, 2H, *J*=7.3 Hz), 7.27 (br, 1H), 7.57 (d, 1H, *J*=7.9 Hz), 8.03 (dd, 1H, *J*=5.5, 7.9 Hz), 8.20 (d, 1H, *J*=7.9 Hz), 8.46 (br, 2H), 9.13 (s, 1H), 9.41 (d, 1H, *J*=5.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 25.72, 26.09, 28.94, 29.02, 29.12, 29.28, 29.32, 29.40, 29.45, 30.37, 30.98, 32.05, 32.76,

32.96, 62.03, 62.81, 123.63, 127.93, 136.68, 138.53, 142.98, 143.87, 144.15, 144.41, 146.24, 148.94; MS (FAB) 537 (M)<sup>+</sup>; HRMS (FAB) obsd.  $m/z$ =537.4797, C<sub>36</sub>H<sub>61</sub>N<sub>2</sub>O requires  $m/z$  537.4784.

**Cyclostelletamine C bis(trifluoromethanesulfonate) (1a).** Collidine (16.7  $\mu$ L, 127  $\mu$ mol) and Tf<sub>2</sub>O (21.3  $\mu$ L, 127  $\mu$ mol) were added to a solution of **20** (29 mg, 42.2  $\mu$ mol) in CH<sub>2</sub>Cl<sub>2</sub> (84 mL) at -20 °C. The solution was stirred at rt for 30 min and then at 30 °C for 30 min. MeOH was then added to the solution at 0 °C. The solution was concentrated and the residual oil was purified by LH-20 gel column chromatography (MeOH and then CHCl<sub>3</sub>-MeOH, 1:1) to give **1a** (27 mg, 78%) as a colorless amorphous solid: mp 123-124 °C (crystallized from EtOAc-hexane); <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.20-1.38 (m, 36H), 1.71 (m, 4H), 2.00 (m, 4H), 2.88 (t, 4H,  $J$ =7.3 Hz), 4.65 (t, 4H,  $J$ =7.1 Hz), 7.97 (dd, 2H,  $J$ =5.9, 7.8 Hz), 8.23 (d, 2H,  $J$ =7.8 Hz), 8.72 (d, 2H,  $J$ =5.9 Hz), 8.81 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  25.66, 28.22, 28.29, 28.38, 28.42, 28.51, 29.28, 29.50, 30.07, 31.71, 32.66, 62.25, 120.82 ( $J$ =313 Hz), 127.89, 141.81, 144.40, 144.71, 144.90; MS (FAB) 260 (M/2)<sup>+</sup>, 519 (M-H)<sup>+</sup>, 669 (M+TfO)<sup>+</sup>; HRMS (FAB) obsd.  $m/z$ =519.4655, C<sub>36</sub>H<sub>59</sub>N<sub>2</sub> requires  $m/z$  519.4678; obsd.  $m/z$ =669.4277, C<sub>36</sub>H<sub>60</sub>N<sub>2</sub>CF<sub>3</sub>O<sub>3</sub>S requires  $m/z$  669.4277; UV (MeOH)  $\lambda_{\text{max}}$  266 nm ( $\epsilon$  6230). Anal. Calcd. for C<sub>38</sub>H<sub>60</sub>N<sub>2</sub>O<sub>6</sub>F<sub>6</sub>S<sub>2</sub>: C, 55.73; H, 7.38; N, 3.42; F, 13.92; S, 7.83. Found: C, 55.18; H, 7.21; N, 3.47; F, 13.95; S, 8.08.

**1-(CF<sub>3</sub>CO<sub>2</sub>) (1b).** HRMS (FAB) obsd.  $m/z$ =519.4699, C<sub>36</sub>H<sub>59</sub>N<sub>2</sub> requires  $m/z$  519.4678; obsd.  $m/z$ =633.4620, C<sub>36</sub>H<sub>60</sub>N<sub>2</sub>CF<sub>3</sub>CO<sub>2</sub> requires  $m/z$  633.4607.

**1-2Cl (1c).** HRMS (FAB) obsd.  $m/z$ =519.4708, C<sub>36</sub>H<sub>59</sub>N<sub>2</sub> requires  $m/z$  519.4678; obsd.  $m/z$ =555.4448, C<sub>36</sub>H<sub>60</sub>N<sub>2</sub>Cl requires  $m/z$  555.4445.

**3-(13-Hydroxytridecyl)pyridine (19).** TfOH (0.217 mL, 2.45 mmol) and TMSI (0.413 mL, 2.90 mmol) were added to a solution of **8** (820 mg, 2.23 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and stirred at rt for 13 h. The reactant was poured into MeOH (30 mL) to quench the reaction. Anhydrous Na<sub>2</sub>SO<sub>3</sub> was added, and the mixture was stirred at rt for 30 min. After filtration, 40% MeNH<sub>2</sub> in MeOH (6 mL)<sup>12)</sup> was added, and the mixture stirred at rt for 30 min. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography (EtOAc-hexane, 1:5 to 1:1) to give **19** (500 mg, 81%) as colorless needles: mp 46-47 °C; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.20-1.40 (m, 18H), 1.53-1.66 (m, 4H), 1.82 (br, 1H), 2.60 (t, 2H,  $J$ =7.6 Hz), 3.64 (t, 2H,  $J$ =6.6 Hz), 7.20 (dd, 1H,  $J$ =4.9, 7.8 Hz), 7.49 (d, 1H,  $J$ =7.8 Hz), 8.44 (m, 2H); MS (FAB) 278 (M+H)<sup>+</sup>; HRMS (EI) obsd.  $m/z$ =277.2417, C<sub>18</sub>H<sub>31</sub>NO requires  $m/z$  277.2406.

**Cyclic monomer (21).** Tf<sub>2</sub>O (66  $\mu$ L, 389  $\mu$ mol) and <sup>1</sup>Pr<sub>2</sub>NEt (68  $\mu$ L, 389  $\mu$ mol) were added to a solution of **19** (83 mg, 299  $\mu$ mol) in 1,2-dichloromethane (150 mL) at -20 °C. After stirring at the same temperature for 30 min then at rt for 3 h, Tf<sub>2</sub>O (15 mL, 90  $\mu$ mol) was added again. After 18 h, MeOH (2 mL) was added to the mixture, which was concentrated. The residue was purified by LH-20 gel column chromatography (MeOH) and reversed phase column chromatography (MeOH-H<sub>2</sub>O, 9:1) to afford **21** (50 mg, 41%) and **1a** (9.8 mg, 4%). **21** (a colorless amorphous solid): <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.08-1.32 (m, 18H), 1.80 (m, 2H), 2.06 (m, 2H), 2.96 (t, 2H,  $J$ =6.4 Hz), 4.94 (t, 2H,  $J$ =5.8 Hz), 8.05 (dd, 1H,  $J$ =6.1, 7.9 Hz), 8.26 (d, 1H,  $J$ =7.9 Hz), 8.98 (s, 1H), 9.29 (d, 1H,  $J$ =6.1

Hz);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  24.08, 26.20, 26.26, 26.33, 26.76, 26.83, 26.88, 28.95, 30.58, 31.88, 61.79, 120.71 ( $J=320$  Hz), 128.03, 142.96, 143.79, 144.12, 145.13; HRMS (FAB) obsd.  $m/z=260.2376$ ,  $\text{C}_{18}\text{H}_{30}\text{N}$  requires  $m/z$  260.2378; UV (MeOH)  $\lambda_{\text{max}}$  267 nm ( $\epsilon$  4100).

**1-Butyl-3-(3-benzyloxypropyl)pyridinium iodide (16).** A mixture of 3-(3-benzyloxypropyl)pyridine (3.3 g, 14.5 mmol), which was synthesized from 3-(3-hydroxypropyl)pyridine in a 67% yield in the same manner as **3**, and butyliodide (1.65 mL, 14.5 mmol) in THF (20 mL) was heated under reflux for 6 h. The reaction mixture was concentrated, and the residue was purified by silica gel column chromatography ( $\text{CHCl}_3$ -MeOH, 10:1) to give **16** (2.88 g, 48%) as a colorless oil:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.95 (t, 3H,  $J=7.3$  Hz), 1.16-1.55 (m, 2H), 1.80-2.25 (m, 4H), 3.06 (t, 2H,  $J=7.6$  Hz), 3.56 (t, 2H,  $J=5.8$  Hz), 4.47 (s, 2H), 4.84 (t, 2H,  $J=7.4$  Hz), 7.20-7.40 (m, 5H), 7.95 (dd, 1H,  $J=6.3$ , 8.0 Hz), 8.25 (d, 1H,  $J=8.0$  Hz), 9.14 (d, 1H,  $J=6.3$  Hz), 9.18 (s, 1H); MS (FAB) 284 ( $\text{M}^+$ ); HRMS (FAB) obsd.  $m/z=284.2011$ ,  $\text{C}_{19}\text{H}_{26}\text{NO}$  requires  $m/z$  284.2014.

**1-Butyl-3-(3-hydroxypropyl)pyridinium iodide (17).** The typical procedure is as follows: TMSI (0.22 mL, 1.58 mmol) was added to a solution of **16** (500 mg, 1.22 mmol) in  $\text{CH}_2\text{Cl}_2$  (12 mL), and the mixture stirred at rt for 30 min. MeOH (12 mL) was added to the mixture, followed by the addition of  $\text{Na}_2\text{SO}_3$ . After stirring for 30 min, the reaction mixture was concentrated after filtration and purified by silica gel (deactivated with 6%w/w water) column chromatography ( $\text{CHCl}_3$ -MeOH, 10:1) to furnish **17** (351 mg, 90%) and **18** (31 mg, 6%). **17**:  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ )  $\delta$  0.99 (t, 3H,  $J=6.8$  Hz), 1.15-1.68 (m, 2H), 1.82-2.25 (m, 4H), 3.01 (t, 2H,  $J=7.9$  Hz), 3.63 (t, 2H,  $J=6.2$  Hz), 4.70 (t, 2H,  $J=7.6$  Hz), 8.06 (dd, 1H,  $J=5.9$ , 8.0 Hz), 8.53 (d, 1H,  $J=8.0$  Hz), 8.94 (d, 1H,  $J=5.9$  Hz), 9.07 (s, 1H); MS (FAB) 194 ( $\text{M}^+$ ); HRMS (FAB) obsd.  $m/z=194.1561$ ,  $\text{C}_{12}\text{H}_{20}\text{NO}$  requires  $m/z$  194.1545. **18**:  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  0.99 (t, 3H,  $J=6.7$  Hz), 1.21-1.70 (m, 2H), 1.78-1.50 (m, 4H), 3.11 (t, 2H,  $J=7.9$  Hz), 3.25 (t, 2H,  $J=6.4$  Hz), 4.93 (t, 2H,  $J=7.5$  Hz), 8.05 (dd, 1H,  $J=5.8$ , 8.5 Hz), 8.36 (d, 1H,  $J=8.5$  Hz), 9.13 (d, 1H,  $J=5.8$  Hz), 9.43 (s, 1H); MS (FAB) 304 ( $\text{M}^+$ ); HRMS (FAB) obsd.  $m/z=304.0556$ ,  $\text{C}_{12}\text{H}_{19}\text{NI}$  requires  $m/z$  304.0562.

## ACKNOWLEDGMENT

We are grateful to Mr. Fukushi Hirayama and Mr. Jun-ichi Kazami for their kind advice and to the staff of the Division of Analytical Research Laboratory for the elemental analyses and spectral measurements.

## REFERENCES AND NOTES

- Schmitz, F. J.; Hollenbeak, K. H.; Campbell, D. C. *J. Org. Chem.* **1978**, 43, 3916-3922. Fusetani, N.; Yasumuro, K.; Matsunaga, S.; Hirota, H. *Tetrahedron Lett.* **1989**, 30, 6891-1894. Talpir, R.; Rudi, A.; Ilan, M.; Kashman, Y. *Tetrahedron Lett.* **1992**, 33, 3033-3034.
- Fusetani, N.; Asai, N.; Matsunaga, S.; Honda, K.; Yasumuro, K. *Tetrahedron Lett.* **1994**, 35, 3967-3970.
- Davies-Coleman, M. T.; Faulkner, D. J.; Dubowchik, G. M.; Roth, G. P.; Polson, C.; Fairchild, C. *J. Org.*

- Chem.* **1993**, 58, 5925-5930.
4. Classon, B.; Liu, Z.; Samuelsson, B. *J. Org. Chem.* **1988**, 53, 6126-6130.
  5. The counter anions of **13** were both  $\Gamma^-$  and  $\text{TfO}^-$ . The yield of **13** was then calculated with an  $\Gamma^-/\text{TfO}^-$  ratio of 1/1.
  6. Other more polar products were produced as inseparable mixtures but they were not characterized.
  7. Jung, M. E.; Lyster, M. A. *J. Org. Chem.* **1977**, 42, 3761-3764.
  8. **8** was stable under the acidic conditions (3N HCl aqueous EtOH at 80 °C overnight), but hydrogenation on Pd/C (existence of a catalytic amount of HCl) gave a polar and nonfluorescent product.
  9. Natural cyclostelletamine C was purified by HPLC, giving a major counter anion of  $\text{CF}_3\text{CO}_2^-$ .
  10. Yazawa, H.; Honda, K. *Japan. J. Pharmacol.* **1993**, 61, 319-324.
  11. Wess, J. *Trends Pharmacol. Sci.*, **1993**, 14, 308-313.
  12. Benzyliodide, which was produced over this reaction, was trapped as BnNHMe to prevent reaction with the pyridine moiety of the required product and to facilitate separation.

(Received in Japan 11 April 1996; accepted 1 July 1996)